Role of animal models in understanding intravesical therapy with Bacille Calmette-Guérin

Clinical Infectious Diseases

Volumn 31, Issue SUPPL. 3, 2000, Pages

  Ratliff, T L ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; FIBRONECTIN RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1ALPHA; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; BCG VACCINATION; BLADDER CANCER; CANCER IMMUNOTHERAPY; CONFERENCE PAPER; DELAYED HYPERSENSITIVITY; MUCOSAL IMMUNITY; MYCOBACTERIUM BOVIS; MYCOBACTERIUM LEPRAE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TH2 CELL;

ADMINISTRATION, INTRAVESICAL; ANIMALS; BCG VACCINE; CANCER VACCINES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY; MICE; URINARY BLADDER NEOPLASMS;

EID: 0034454497     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/314065     Document Type: Conference Paper

References (9)

1. Characterization of the internalization of bacillus Calmette-Guérin by human bladder tumor cells
2. A Mycobacterium leprae gene encoding a fibronectin-binding protein is used for efficient invasion of epithelial cells and Schwann cells
3. Modulation of BCG-fibronectin binding through use of drugs influencing the coagulation pathway
4. Choice of an optimal diluent for intravesical BCG administration
5. T cell subsets required for intravesical BCG immunotherapy for bladder cancer
6. + Thl effectors
7. Tumor-induced interleukin-10 inhibits type I immune responses directed at a tumor antigen as well as a nonrumor antigen present at the tumor site
8. IFN-α 2B enhances the ThI cytokine responses in bladder cancer patients receiving Mycobacterium bovis BCG immunotherapy
9. Increased antimycobacterial immunity in interleukin-10-deficient mice